Becky Carlyle Co-Leads New Alzheimer’s Disease Research Project at the IMCM

Becky Carlyle Co-Leads New Alzheimer’s Disease Research Project at the IMCM

Dr. Becky Carlyle, Team Leader at Kavli Oxford, is co-leading an innovative Alzheimer’s Disease research project at the GSK Institute of Molecular and Computational Medicine (IMCM), a pioneering collaboration between the University of Oxford and GSK.

 

Becky Carlyle Main Photo

 

The project, co-led by Professor Laura Parkkinen and GSK leads Dr. Sanjay Kumar and Dr. Andy Goldfine, aims to identify markers of disease heterogeneity and progression in Alzheimer’s Disease. The team includes Dr. Hugo Fernandes (Kavli Oxford & DPAG), Sally Cowley (Dunn School), and Laura Winchester (Psychiatry).

 

The research focuses on three advanced strands:

  • AI-driven neuropathology to enhance the analysis of brain tissue.
  • Multi-omic characterisation of patient biofluids and brain tissue to uncover molecular insights.
  • Functional analyses of iPSC-derived microglia and neurons to explore cellular mechanisms.

 

The ultimate goal is to develop biomarkers for improving patient selection in clinical trials and to deepen understanding of Alzheimer’s disease mechanisms and progression.

For more information about the IMCM, visit imcm.ox.ac.uk.

Since April 2021, Oxford University's KAVLI Institute for Nanoscience Discovery is proudly serving as a hub for research groups from seven different departments spanning both the medical and physical sciences, including Carlyle Group from the Department of Physiology, Anatomy and Genetics.

6 December 2024